785 related articles for article (PubMed ID: 16323121)
1. The role of vancomycin in the treatment paradigm.
Stevens DL
Clin Infect Dis; 2006 Jan; 42 Suppl 1():S51-7. PubMed ID: 16323121
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
Madrigal AG; Basuino L; Chambers HF
Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of Staphylococcus aureus to vancomycin: analysis of minimum inhibitory concentrations in two tertiary care hospitals in eastern South Dakota.
Laible BR; Hellwig TR; Hedge DD
S D Med; 2011 Mar; 64(3):91-5. PubMed ID: 21473519
[TBL] [Abstract][Full Text] [Related]
4. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
[TBL] [Abstract][Full Text] [Related]
5. Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin.
Woods CW; Cheng AC; Fowler VG; Moorefield M; Frederick J; Sakoulas G; Meka VG; Tenover FC; Zwadyk P; Wilson KH
Clin Infect Dis; 2004 Apr; 38(8):1188-91. PubMed ID: 15095227
[TBL] [Abstract][Full Text] [Related]
6. Treatment of staphylococcal infections with cyclic lipopeptides.
Eisenstein BI
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():10-6. PubMed ID: 18226085
[TBL] [Abstract][Full Text] [Related]
7. Key considerations in the treatment of complicated staphylococcal infections.
Jones RN
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084
[TBL] [Abstract][Full Text] [Related]
8. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
[TBL] [Abstract][Full Text] [Related]
9. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.
Charles PG; Ward PB; Johnson PD; Howden BP; Grayson ML
Clin Infect Dis; 2004 Feb; 38(3):448-51. PubMed ID: 14727222
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of MRSA infections].
Borde JP; Kern WV
Dtsch Med Wochenschr; 2012 Dec; 137(49):2553-7. PubMed ID: 23143638
[No Abstract] [Full Text] [Related]
11. Limitations of vancomycin in the management of resistant staphylococcal infections.
Kollef MH
Clin Infect Dis; 2007 Sep; 45 Suppl 3():S191-5. PubMed ID: 17712746
[TBL] [Abstract][Full Text] [Related]
12. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin.
Mohan SS; McDermott BP; Cunha BA
Heart Lung; 2005; 34(1):69-71. PubMed ID: 15647736
[TBL] [Abstract][Full Text] [Related]
13. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
[TBL] [Abstract][Full Text] [Related]
14. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study.
Chang FY; Peacock JE; Musher DM; Triplett P; MacDonald BB; Mylotte JM; O'Donnell A; Wagener MM; Yu VL
Medicine (Baltimore); 2003 Sep; 82(5):333-9. PubMed ID: 14530782
[TBL] [Abstract][Full Text] [Related]
15. Evidence of less severe aortic valve destruction after treatment of experimental staphylococcal endocarditis with vancomycin and dexamethasone.
Siaperas P; Pefanis A; Iliopoulos D; Katsarolis I; Kyroudi-Voulgari A; Donta I; Karayiannakos P; Giamarellou H
Antimicrob Agents Chemother; 2001 Dec; 45(12):3531-7. PubMed ID: 11709335
[TBL] [Abstract][Full Text] [Related]
16. [Use of vancomycin in the treatment of severe Staphylococcus aureus infection. Description of 3 cases].
Campelli A; Mantero E; Fabbri A; Nahum M; Ferraris R; Di Noto C
Minerva Med; 1984 Feb; 75(8):385-90. PubMed ID: 6709217
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin.
Price J; Atkinson S; Llewelyn M; Paul J
Clin Infect Dis; 2009 Apr; 48(7):997-8. PubMed ID: 19260820
[No Abstract] [Full Text] [Related]
18. Staphylococcus aureus bloodstream infections: definitions and treatment.
Corey GR
Clin Infect Dis; 2009 May; 48 Suppl 4():S254-9. PubMed ID: 19374581
[TBL] [Abstract][Full Text] [Related]
19. New agents for Staphylococcus aureus endocarditis.
Drees M; Boucher H
Curr Opin Infect Dis; 2006 Dec; 19(6):544-50. PubMed ID: 17075329
[TBL] [Abstract][Full Text] [Related]
20. Caution when reconsidering empiric antimicrobial therapy for methicillin-resistant Staphylococcus aureus skin and soft-tissue infections.
da Silva LV; Zavascki AP; de Souza MV; Marcadenti A
Am J Surg; 2008 Oct; 196(4):618-9. PubMed ID: 18809069
[No Abstract] [Full Text] [Related]
[Next] [New Search]